The Role of Immunotherapy in Solid Malignancies: Biological Rationale, Clinical Evidence and Future Directions

Abstract

Sanjaya K Upadhyaya

Immunotherapy—especially immune checkpoint inhibitors (ICIs)—has reshaped the therapeutic landscape of solid tumors by restoring antitumor immunity through blockade of the programmed cell death protein 1/programmed death- ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) axes. The mechanistic foundation of ICI efficacy includes reversal of T-cell exhaustion, enhancement of antigen presentation, and remodeling of the tumor immune microenvironment (TME). Clinically, immune checkpoint blockade has expanded from early successes in melanoma and lung cancer to become integral across gastrointestinal, hepatobiliary, renal, gynecologic, breast, and molecularly selected colorectal cancers, with accelerating incorporation into perioperative and curative-intent strategies. Yet, broad benefit remains constrained by primary and acquired resistance, imperfect biomarkers, and immune- related adverse events (irAEs). This review synthesizes biologic principles, pivotal and contemporary trial evidence, and evolving clinical applications across major solid tumor groups, with emphasis on recent perioperative advances (2023–2025), circulating tumor DNA (ctDNA)-guided concepts, microbiome influences, combination immunotherapy strategies, and emerging cellular and adoptive immunotherapies. We highlight practical biomarker frameworks, toxicity recognition/management, and future directions that include next-generation checkpoints, engineered cell therapies, microbiome modulation, and adaptive treatment paradigms to extend durable benefit safely and equitably.

PDF